Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherSPECIAL CONTRIBUTIONS

FDG PET Imaging in Patients with Pathologically Verified Dementia

John M. Hoffman, Kathleen A. Welsh-Bohmer, Michael Hanson, Barbara Crain, Christine Hulette, Nancy Earl and R. Edward Coleman
Journal of Nuclear Medicine November 2000, 41 (11) 1920-1928;
John M. Hoffman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen A. Welsh-Bohmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Hanson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Crain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Hulette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Earl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Edward Coleman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The purpose of this study was to confirm with pathologic verification 2 beliefs related to Alzheimer's disease (AD): (a) the long-standing impression that bilateral temporo-parietal hypometabolism, as noted on FDG PET imaging, is the metabolic abnormality associated with Alzheimer's disease (AD) and (b) that the sensitivity, specificity, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism allows differentiation between other degenerative causes of dementia. Methods: Twenty two individuals (8 women, 14 men) with difficult-to-characterize memory loss or dementia (using standard clinical criteria), and who eventually received pathologic confirmation of diagnosis, were evaluated. FDG PET brain scans were obtained and visually graded by an experienced nuclear medicine physician as to the presence of classic bilateral temporo-parietal hypometabolism as seen in Alzheimer's type dementia. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism were determined using pathologic diagnosis as the gold standard. Results: The clinical diagnosis of possible or probable AD was determined as the primary cause of dementia in 12 patients. The sensitivity and specificity of the clinical diagnosis for probable AD were 63% and 100%, respectively. The sensitivity and specificity of the clinical diagnosis for possible and probable AD were 75% and 100%, respectively. The sensitivity, specificity, and diagnostic accuracy of bilateral temporo-parietal hypometabolism being associated with AD were 93%, 63%, and 82%, respectively. Conclusion: This study confirms that bilateral temporo-parietal hypometabolism is indeed the classic metabolic abnormality associated with AD. Furthermore, in individuals with dementia whose FDG PET scans indicated a metabolic pattern other than bilateral temporo-parietal hypometabolism, a cause of dementia other than AD should be suspected. These observations may be of clinical importance in differentiating dementia syndromes. The sensitivity, specificity, and diagnostic accuracy of FDG PET are acceptable as tests to be used in the evaluation of dementia and particularly to confirm the clinical suspicion of AD.

  • dementia
  • FDG PET
  • Alzheimer's disease

Footnotes

  • Received May 3, 1999; revision accepted Mar. 2, 2000.

    For correspondence or reprints contact: John M. Hoffman, MD, National Cancer Institute NCI/DCTD/DIP EPN/800, Diagnostic Imaging Program, 6130 Executive Blvd., MSC 7440, Bethesda, MD 20892-7440.

View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 41, Issue 11
November 1, 2000
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FDG PET Imaging in Patients with Pathologically Verified Dementia
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
FDG PET Imaging in Patients with Pathologically Verified Dementia
John M. Hoffman, Kathleen A. Welsh-Bohmer, Michael Hanson, Barbara Crain, Christine Hulette, Nancy Earl, R. Edward Coleman
Journal of Nuclear Medicine Nov 2000, 41 (11) 1920-1928;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FDG PET Imaging in Patients with Pathologically Verified Dementia
John M. Hoffman, Kathleen A. Welsh-Bohmer, Michael Hanson, Barbara Crain, Christine Hulette, Nancy Earl, R. Edward Coleman
Journal of Nuclear Medicine Nov 2000, 41 (11) 1920-1928;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Evaluating Dementia Using PET: How Do We Put into Clinical Perspective What We Know to Date?
  • PubMed
  • Google Scholar

Cited By...

  • BOLD Amplitude Correlates of Preclinical Alzheimers Disease
  • Multi-transcriptomic analysis points to early organelle dysfunction in human astrocytes in Alzheimers disease
  • A machine-learning approach for detection of local brain networks and marginally weak signals identifies novel AD/MCI differentiating connectomic neuroimaging biomarkers
  • Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
  • Brain imaging in dementia
  • Biomarkers in dementia: clinical utility and new directions
  • Association of hypometabolism and amyloid levels in aging, normal subjects
  • Diagnostic tests for Alzheimer disease: Judicious use can be helpful in clinical practice
  • The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment
  • Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies
  • Brain Imaging in Alzheimer Disease
  • Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature
  • A tale of two tracers: The age of wisdom for dementia diagnosis?
  • Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients
  • Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment
  • Imaging Approaches to Parkinson Disease
  • What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
  • Comparison of Regional Brain Volume and Glucose Metabolism Between Patients with Mild Dementia with Lewy Bodies and Those with Mild Alzheimer's Disease
  • Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease
  • APOE related alterations in cerebral activation even at college age
  • Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging
  • Evaluating Early Dementia With and Without Assessment of Regional Cerebral Metabolism by PET: A Comparison of Predicted Costs and Benefits
  • Direct Comparison of Spatially Normalized PET and SPECT Scans in Alzheimer's Disease
  • SPECT Imaging in Dementias
  • Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
  • A Tabulated Summary of the FDG PET Literature
  • Evaluating Dementia Using PET: How Do We Put into Clinical Perspective What We Know to Date?
  • Google Scholar

More in this TOC Section

  • The Use of Published Clinical Study Reports to Support U.S. Food and Drug Administration Approval of Imaging Agents
  • Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites
  • American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET
Show more Special Contributions

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire